methyl 6-(2-bromoacetyl)picolinate | 135450-56-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: methyl 6-(2-bromoacetyl)picolinate
• 英文别名: Ro 25-6142；Methyl 6-(2-bromoacetyl)pyridine-2-carboxylate
• CAS: 135450-56-5
• 化学式: C₉H₈BrNO₃
• 分子量: 258.071
• InChiKey: IYMRKJLWSZFIQH-UHFFFAOYSA-N

物化性质

• 沸点：
  364.1±32.0 °C(Predicted)
• 密度：
  1.561±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  56.3
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  methyl 6-(2-bromoacetyl)picolinate 在 sodium hydroxide 作用下， 以 1,4-二氧六环 、 甲醇 为溶剂， 反应 2.0h， 生成 6-(2-Methyl-thiazol-4-yl)-pyridine-2-carboxylic acid
  参考文献：
  名称：

  Synthesis of novel substituted pyridines as inhibitors of endothelin coverting enzyme-1 (ECE-1)

  摘要：

  A series of bi-aryl pyridine carboxylic acids has been prepared and evaluated as inhibitors of ECE-1. The analogs were prepared by Pd catalyzed cross couplings of halogenated pyridines with heteroaryl organo -boranes, -tinate or -zincate derivatives. (C) 1998 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(98)00375-8
• 作为产物：
  描述：

  吡啶-2.6-二羧酸二甲酯 在 氢氧化钾 、 草酰氯 、 氢溴酸 、 N,N-二甲基甲酰胺 作用下， 以 四氢呋喃 、 甲醇 、 乙醚 、 氯仿 、 水 为溶剂， 反应 4.5h， 生成 methyl 6-(2-bromoacetyl)picolinate
  参考文献：
  名称：

  通过对映选择性恶唑硼烷催化的还原反应合成Ro 25-8210

  摘要：

  在过量的硼烷存在下，用手性恶唑硼烷环烷对映异构地还原了含有氮原子的前手性酮。然而，对于这种不对称还原，吡啶体系已被证明是较差的底物。例如，用手性恶唑硼烷催化还原2-乙酰基吡啶仅提供28％ee的产物醇。我们希望报道手性恶唑硼烷啶对2-（溴乙酰基）-吡啶1的对映选择性还原。还原得到良好的对映体过量（80％ee），重结晶后可提高到≥95％ee。随后，使用溴代醇6制备Ro 25-8210。

  DOI：

  10.1016/s0040-4020(97)00802-8

文献信息

• PIPERIDINE-AMIDE DERIVATIVES
  申请人：Andjelkovic Mirjana

  公开号：US20080300279A1

  公开（公告）日：2008-12-04

  The invention is concerned with novel piperidine-amide derivatives of formula (I) wherein R 1 , R 2 , X and Y are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compounds inhibit L-CPT1 and may be used to treat diseases associated with L-CPT1.

  这项发明涉及式（I）中的新型哌啶酰胺衍生物，其中R1、R2、X和Y如描述和权利要求中定义，并且其生理上可接受的盐和酯。这些化合物抑制L-CPT1，可用于治疗与L-CPT1相关的疾病。
• PROCESS FOR PREPARATION OF (S)-ALPHA-HALOME THYLPYRIDINE METHANOL DERIVATIVES
  申请人：KANEKA CORPORATION

  公开号：EP1454899A1

  公开（公告）日：2004-09-08

  The present invention provides a process for easily preparing a (S)-α-halomethylpyridine-methanol derivative, which is useful as an intermediate of pharmaceutical products, from inexpensive raw materials. The (S)-α-halomethylpyridine-methanol derivative is prepared by (S)-selectively reducing a 2-haloacetylpyridine derivative using an enzyme source having ability to (S)-selectively reduce a carbonyl group of the 2-haloacetylpyridine derivative, which can be obtained inexpensively. Also, a hydrohalic acid salt of (S)-α-halomethyl-3-pyridine-methanol derivative is isolated and purified as crystal from a (S)-α-halomethyl-3-pyridine-methanol derivative containing impurities using hydrohalic acid and an organic solvent.

  本发明提供了一种从廉价原料中轻松制备(S)-α-卤甲基吡啶-甲醇衍生物的方法，该衍生物可用作制药产品的中间体。该(S)-α-卤甲基吡啶-甲醇衍生物是通过使用具有(S)-选择性还原2-卤乙酰吡啶衍生物的羧酸还原酶源制备的，该酶源能够(S)-选择性地还原2-卤乙酰吡啶衍生物，而该酶源可以廉价获得。此外，使用氢卤酸和有机溶剂从含杂质的(S)-α-卤甲基-3-吡啶甲醇衍生物中分离纯化出(S)-α-卤甲基-3-吡啶甲醇衍生物的氢卤酸盐晶体。
• Process for preparation of (s)-alpha-halomethylpyridine-methanol derivatives
  申请人：——

  公开号：US20040265991A1

  公开（公告）日：2004-12-30

  The present invention provides a process for easily preparing a (S)-&agr;-halomethylpyridine-methanol derivative, which is useful as an intermediate of pharmaceutical products, from inexpensive raw materials. The (S)-&agr;-halomethylpyridine-methanol derivative is prepared by (S)-selectively reducing a 2-haloacetylpyridine derivative using an enzyme source having ability to (S)-selectively reduce a carbonyl group of the 2-haloacetylpyridine derivative, which can be obtained inexpensively. Also, a hydrohalic acid salt of (S)-&agr;-halomethyl-3-pyridine-methanol derivative is isolated and purified as crystal from a (S)-&agr;-halomethyl-3-pyridine-methanol derivative containing impurities using hydrohalic acid and an organic solvent.

  本发明提供了一种从廉价原料中轻松制备(S)-α-卤甲基吡啶甲醇衍生物的方法，该衍生物可用作制药产品的中间体。通过使用具有(S)-选择性还原2-卤乙酰吡啶衍生物的能力的酶源(S)-选择性还原2-卤乙酰吡啶衍生物来制备(S)-α-卤甲基吡啶甲醇衍生物，该酶源可以廉价获得。此外，使用氢卤酸和有机溶剂从含杂质的(S)-α-卤甲基-3-吡啶甲醇衍生物中分离和纯化(S)-α-卤甲基-3-吡啶甲醇衍生物的氢卤酸盐作为晶体。
• New thiazole derivatives, processes for the preparation thereof and pharmaceutical compositon comprising the same
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：EP0417751A2

  公开（公告）日：1991-03-20

  A compound of the formula : wherein R' is amino which may have suitable substituent ( s). hydroxy. halogen, cyano, acyl, heterocyclic thio, heterocyclic group or a group of the formula : in which R4 is hydrogen, cyano or acyl. and R5 is amino or lower alkoxy. R2 and R3 are each hydrogen, acyl or lower alkyl which may have halogen: or R2 and R3 are linked together to form lower alkylene. in which R6 is hydrogen or halogen, and A is bond or lower alkylene, provided that when R1 is amino which may have suitable substituent(s) and A is bond; or R1 is lower alkylthioureido and A is lower alkylene, then and pharmaceutically acceptable salt thereof, processes for their preparation and pharmaceutical compositions comprising them as an active. ingredient.

  式中的化合物 其中 R'为氨基，可具有合适的取代基（s）、羟基、卤素、氰基、酰基、杂环硫基、杂环基团或式......的基团： 其中 R4 是氢、氰基或酰基。 R5 是氨基或低级烷氧基。 R2 和 R3 各为氢、酰基或低级烷基，其中可含卤素：或 R2 和 R3 连接在一起形成低级亚烷基。 其中 R6 是氢或卤素，以及 A 是键或低级亚烷基、 条件是 当 R1 是氨基，可有适当的取代基，且 A 为键；或 R1 为低级烷基硫脲基，且 A 为低级亚烷基时 且 A 为低级亚烷基，则 以及它们的药学上可接受的盐、它们的制备方法和含有它们作为活性成分的药物组合物。
• Structure-Guided Rescaffolding of Selective Antagonists of BCL-X_L
  作者：Michael F. T. Koehler、Philippe Bergeron、Edna F. Choo、Kevin Lau、Chudi Ndubaku、Danette Dudley、Paul Gibbons、Brad E. Sleebs、Carl S. Rye、George Nikolakopoulos、Chinh Bui、Sanji Kulasegaram、Wilhelmus J. A. Kersten、Brian J. Smith、Peter E. Czabotar、Peter M. Colman、David C. S. Huang、Jonathan B. Baell、Keith G. Watson、Lisa Hasvold、Zhi-Fu Tao、Le Wang、Andrew J. Souers、Steven W. Elmore、John A. Flygare、Wayne J. Fairbrother、Guillaume Lessene

  DOI：10.1021/ml500030p

  日期：2014.6.12

  Because of the promise of BCL-2 antagonists in combating chronic lymphocytic leukemia (CLL) and non-Hodgkin's lymphoma (NHL), interest in additional selective antagonists of antiapoptotic proteins has grown. Beginning with a series of selective, potent BCL-X-L antagonists containing an undesirable hydrazone functionality, in silico design and X-ray crystallography were utilized to develop alternative scaffolds that retained the selectivity and potency of the starting compounds.